MA47676A - Polythérapie - Google Patents
PolythérapieInfo
- Publication number
- MA47676A MA47676A MA047676A MA47676A MA47676A MA 47676 A MA47676 A MA 47676A MA 047676 A MA047676 A MA 047676A MA 47676 A MA47676 A MA 47676A MA 47676 A MA47676 A MA 47676A
- Authority
- MA
- Morocco
- Prior art keywords
- polytherapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17158607 | 2017-03-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47676A true MA47676A (fr) | 2021-06-02 |
Family
ID=58192228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047676A MA47676A (fr) | 2017-03-01 | 2018-02-28 | Polythérapie |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11224596B2 (fr) |
| EP (1) | EP3589323B1 (fr) |
| JP (2) | JP7307682B2 (fr) |
| KR (2) | KR20190121315A (fr) |
| CN (1) | CN110831630A (fr) |
| BR (1) | BR112019017901A2 (fr) |
| EA (1) | EA201991997A1 (fr) |
| MA (1) | MA47676A (fr) |
| PH (1) | PH12019502002A1 (fr) |
| WO (1) | WO2018158280A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180022826A (ko) | 2015-07-02 | 2018-03-06 | 얀센 사이언시즈 아일랜드 유씨 | 항균 화합물 |
| KR20180053386A (ko) | 2015-09-17 | 2018-05-21 | 마빈 제이. 밀러 | 마이코박테리아 감염에 대해 유용한 벤질 아민-함유 헤테로사이클릭 화합물 및 조성물 |
| KR20190017948A (ko) | 2016-06-16 | 2019-02-20 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 항균제로서의 헤테로고리 화합물 |
| CN110831630A (zh) | 2017-03-01 | 2020-02-21 | 爱尔兰詹森科学公司 | 组合疗法 |
| US20220235047A1 (en) * | 2019-05-28 | 2022-07-28 | Shionogi & Co., Ltd. | A MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME bc1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN AND CLOFAZIMINE |
| TW202124379A (zh) | 2019-09-10 | 2021-07-01 | 日商鹽野義製藥股份有限公司 | 對分枝桿菌感染有用之含苄胺的５，６－雜芳族化合物 |
| WO2021122996A1 (fr) * | 2019-12-20 | 2021-06-24 | Qurient Co., Ltd. | Forme posologique orale pharmaceutique de q203 |
| WO2021257466A1 (fr) * | 2020-06-15 | 2021-12-23 | The Global Alliance For Tb Drug Development, Inc. | Composition antibactérienne combinée et procédé de thérapie antibactérienne |
| CN112089713B (zh) * | 2020-09-18 | 2022-02-22 | 中国科学院广州生物医药与健康研究院 | 一种基于吡唑并[1,5-a]吡啶类化合物的治疗结核分枝杆菌感染的药物组合物 |
| WO2022119899A1 (fr) * | 2020-12-02 | 2022-06-09 | Shionogi & Co., Ltd. | Médicament destiné au traitement d'une infection mycobactérienne, caractérisé par la combinaison d'un inhibiteur de cytochrome bc1 avec de la clarithromycine ou de l'azithromycine |
| CN115531388B (zh) * | 2022-11-04 | 2024-03-22 | 首都医科大学附属北京胸科医院 | 治疗结核病的药物组合物 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ295528A (en) | 1994-11-15 | 1999-03-29 | Upjohn Co | Bicyclic oxazine and thiazine oxazolidinone antibacterials |
| DK0828741T3 (da) | 1995-05-11 | 2001-11-26 | Upjohn Co | Spirocykliske og bicykliske diazinyl- og carbazinyloxazolidinoner |
| EP1527050B1 (fr) | 2002-07-25 | 2010-04-07 | Janssen Pharmaceutica N.V. | Derives de quinoleine et leur utilisation en tant qu'inhibiteurs mycobacteriens |
| AR042956A1 (es) | 2003-01-31 | 2005-07-13 | Vertex Pharma | Inhibidores de girasa y usos de los mismos |
| MA27360A1 (fr) | 2004-11-23 | 2005-06-01 | Brahim Bennani | Synthese et application des spiro-isoxazolines comme agents anti-tuberculeux |
| EP2134713A2 (fr) | 2006-12-20 | 2009-12-23 | Schering Corporation | Nouveaux inhibiteurs de jnk |
| CL2008001631A1 (es) | 2007-06-06 | 2009-01-02 | Smithkline Beecham Corp | Compuestos derivados de heterociclos sustituidos, con la presencia de un grupo fenoxi, inhibidores de transcriptasa inversa; composicion farmaceutica; y uso en el tratamiento de infecciones virales por vih. |
| TWI498115B (zh) | 2007-12-27 | 2015-09-01 | Daiichi Sankyo Co Ltd | 咪唑羰基化合物 |
| US7666864B2 (en) | 2008-03-26 | 2010-02-23 | Global Alliance For Tb Drug Development | Bicyclic nitroimidazole-substituted phenyl oxazolidinones |
| US8658350B2 (en) | 2008-09-22 | 2014-02-25 | Oregon Health & Science University | Methods for detecting Mycobacterium tuberculosis disease |
| CA2748274A1 (fr) | 2008-12-30 | 2010-07-08 | Millennium Pharmaceuticals, Inc. | Composes heteroaryles utiles en tant qu'inhibiteurs de kinase raf |
| EP2496578A4 (fr) | 2009-11-05 | 2013-08-21 | Univ Notre Dame Du Lac | Composés d'imidazo[1,2-a]pyridine, leur synthèse et procédés pour les utiliser |
| NZ602311A (en) | 2010-03-18 | 2014-08-29 | Pasteur Institut Korea | Anti-infective compounds |
| KR20140093610A (ko) | 2011-04-21 | 2014-07-28 | 재단법인 한국파스퇴르연구소 | 소염 화합물 |
| CA2845169C (fr) | 2011-09-01 | 2022-04-19 | Irm Llc | Composes et compositions en tant qu'inhibiteurs de kinase c-kit |
| KR20140071383A (ko) | 2011-09-01 | 2014-06-11 | 아이알엠 엘엘씨 | C-kit 키나제 억제제로서의 화합물 및 조성물 |
| US9199981B2 (en) | 2011-09-01 | 2015-12-01 | Novartis Ag | Compounds and compositions as C-kit kinase inhibitors |
| HUE032035T2 (en) | 2012-03-02 | 2017-08-28 | Genentech Inc | Amido spirocyclic amide and sulfonamide derivatives |
| KR101918469B1 (ko) | 2012-06-04 | 2018-11-15 | 한국화학연구원 | 바이사이클릭 니트로이미다졸 유도체 또는 이들의 광학이성질체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물 |
| CN104718213B (zh) | 2012-07-18 | 2018-02-27 | 圣母大学 | 5,5‑杂芳族抗感染化合物 |
| KR101650716B1 (ko) | 2012-11-22 | 2016-08-24 | 한국화학연구원 | 바이시클릭니트로이미다졸 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 결핵의 예방 또는 치료용 약학적 조성물 |
| CN109575018A (zh) | 2013-08-02 | 2019-04-05 | 韩国巴斯德研究所 | 一种抗感染化合物 |
| KR101564425B1 (ko) | 2013-11-26 | 2015-10-30 | 한국화학연구원 | 신규한 바이사이클릭 니트로이미다졸 카바메이트 화합물, 이를 제조하는 방법 및 이를 유효성분으로 함유하는 결핵 질환의 예방 또는 치료용 약제학적 조성물 |
| WO2015107482A1 (fr) | 2014-01-17 | 2015-07-23 | Piramal Enterprises Limited | Association pharmaceutique pour traiter la tuberculose |
| CN105524058B (zh) | 2014-10-21 | 2018-03-27 | 广州艾格生物科技有限公司 | 吡唑并[1,5‑a]吡啶类化合物及其应用 |
| JP2017533220A (ja) * | 2014-11-03 | 2017-11-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 結核処置のための多剤療法 |
| KR20180022826A (ko) | 2015-07-02 | 2018-03-06 | 얀센 사이언시즈 아일랜드 유씨 | 항균 화합물 |
| KR20190017948A (ko) | 2016-06-16 | 2019-02-20 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 항균제로서의 헤테로고리 화합물 |
| WO2017216283A1 (fr) | 2016-06-16 | 2017-12-21 | Janssen Sciences Ireland Uc | Composés hétérocycliques utilisés en tant qu'agents antibacteriens |
| CN110831630A (zh) | 2017-03-01 | 2020-02-21 | 爱尔兰詹森科学公司 | 组合疗法 |
-
2018
- 2018-02-28 CN CN201880015042.9A patent/CN110831630A/zh active Pending
- 2018-02-28 US US16/490,677 patent/US11224596B2/en active Active
- 2018-02-28 EA EA201991997A patent/EA201991997A1/ru unknown
- 2018-02-28 EP EP18707713.6A patent/EP3589323B1/fr active Active
- 2018-02-28 KR KR1020197025379A patent/KR20190121315A/ko active IP Right Grant
- 2018-02-28 KR KR1020247012165A patent/KR20240053077A/ko active Application Filing
- 2018-02-28 BR BR112019017901-1A patent/BR112019017901A2/pt unknown
- 2018-02-28 MA MA047676A patent/MA47676A/fr unknown
- 2018-02-28 JP JP2019547409A patent/JP7307682B2/ja active Active
- 2018-02-28 WO PCT/EP2018/054860 patent/WO2018158280A1/fr unknown
-
2019
- 2019-09-02 PH PH12019502002A patent/PH12019502002A1/en unknown
-
2021
- 2021-12-02 US US17/540,299 patent/US11918575B2/en active Active
-
2023
- 2023-01-27 JP JP2023010821A patent/JP2023061973A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023061973A (ja) | 2023-05-02 |
| WO2018158280A1 (fr) | 2018-09-07 |
| US20220088012A1 (en) | 2022-03-24 |
| EP3589323B1 (fr) | 2024-04-03 |
| BR112019017901A2 (pt) | 2020-05-12 |
| US11224596B2 (en) | 2022-01-18 |
| EA201991997A1 (ru) | 2020-01-22 |
| JP2020509040A (ja) | 2020-03-26 |
| JP7307682B2 (ja) | 2023-07-12 |
| US20200016154A1 (en) | 2020-01-16 |
| CN110831630A (zh) | 2020-02-21 |
| US11918575B2 (en) | 2024-03-05 |
| PH12019502002A1 (en) | 2020-06-29 |
| EP3589323A1 (fr) | 2020-01-08 |
| KR20240053077A (ko) | 2024-04-23 |
| KR20190121315A (ko) | 2019-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3731771T3 (da) | V462033dk00 | |
| MA52090A (fr) | Polythérapie | |
| DE202018003363U8 (de) | Handgelenkssphygmomanometer | |
| MA47676A (fr) | Polythérapie | |
| CL2018000524S1 (es) | Golilla | |
| DK3351526T3 (da) | Diisopentylterephthalat | |
| MA46285A (fr) | Polythérapie | |
| MA49921A (fr) | Polythérapie | |
| DK3568655T3 (da) | Rekuperator | |
| MA51576A (fr) | Polythérapie | |
| DK3571580T5 (da) | Load-logical-and-shift-guarded-instruktion | |
| DK3612237T3 (da) | Genterapi | |
| DK3568506T3 (da) | Offeranode | |
| DK3576686T3 (da) | Brokbind | |
| DK3676276T3 (da) | Spirothietannukleosider | |
| DK3576718T3 (da) | Pastil | |
| FI11704U1 (fi) | Liittopuujärjestely | |
| DK3510051T3 (da) | Carboxylalkylchitosan | |
| DK3395159T3 (da) | Ballepresse | |
| ES1205411Y (es) | Maleta-Gaveta | |
| ES1198359Y (es) | Columbario | |
| FI11529U1 (fi) | Ontelolaatan kannake | |
| DK3645955T3 (da) | Buffertank | |
| DK3401461T3 (da) | Falsetagtegl | |
| DK3391733T3 (da) | Ballepresse |